Naimish Patel
Vermogen: 1 M $ op 30-09-2026
Vermogen: 1 M $ op 30-09-2026
Dr. Naimish Patel, MD, is a Chief Medical Officer at CRISPR Therapeutics AG.
He is on the Board of Directors at AgomAb Therapeutics NV.
Dr. Patel was previously employed as a Global Head-Dupilumab Program by Sanofi.
He received his undergraduate degree from Massachusetts Institute of Technology and a doctorate degree from McGill University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 29-05-2026 | 19.357 ( 0,02% ) | 1 M $ | 30-09-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| CRISPR THERAPEUTICS AG | Hoofd Techniek/Wetenschap/O&O | 28-05-2024 |
| AGOMAB THERAPEUTICS NV | Directeur/Bestuurslid | 11-09-2026 |
| Bedrijven | Functie | Einde |
|---|---|---|
| SANOFI | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
Sanofi
Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
McGill University
McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
CRISPR Therapeutics AG
CRISPR Therapeutics AG BiotechnologyHealth Technology Develops gene-based medicines | Health Technology |
AgomAb Therapeutics NV
AgomAb Therapeutics NV BiotechnologyHealth Technology Develops molecular therapies for regeneration of damaged tissues | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau